Theravance Biopharma SVP Reduces Stake; Company Cuts R&D After Phase 3 Setback
Rhonda Farnum, Senior Vice President of Communications and Medical Affairs at Theravance Biopharma, sold 31,067 ordinary shares on March 16, 2026, netting roughly $433,637. The trades were carried out under a 10b5-1 plan and leave Farnum with 232,699 shares. The insider activity comes amid the company’s decision to discontinue the ampreloxetine pro…